GIST Support International - logo

GIST Support International - SF1126
GIST Imagery

SF1126

SF1126, under development by Semafore Pharmaceuticals, is an inhibitor of the PI3K pathway.  This pathway is clearly relevant to GIST.  For information at the manufacturer's site click here.

According to the Semafore news release, SF1126 is available in a Phase I trial being conducted at these locations: 

  • Virginia Piper Cancer Center, Scottsdale
    contact patient care coordinator, Joyce Ingold RN MSN OCN
    TGen Clinical Research Services
    Patient Care Coordinator
    10460 N. 92nd Street, Suite 206
    Scottsdale, AZ 85258
    Office 480-323-1339
    Fax 480-323-1259
    jingold@shc.org
  • Indiana University Cancer Center

The trial name is "A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors."  It is not yet listed on the clinicaltrials.gov website.

For more information please contact TGen Clinical Research Services.



back to top